BioOutsource expands ADC characterisation capabilities
A global leader in ADC characterisation, BioOutsource, partners with Glythera.
Exhibits at World ADC Summit in Frankfurt.
GLASGOW, Scotland. – 18 February 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has amplified its position as a global leader inAntibody Drug Conjugates (ADC) characterisation and are pleased to announce a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne that specializes in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.
“Building on our position as a leader in biological characterisation of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterise their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource CSO, Daniel Galbraith.
Chief Operating Officer at Glythera Dr David Simpson, highlighted the value of the collaboration, “we are delighted to have the opportunity to work with BioOutsource on their ADC characterisation as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”
BioOutsource has also announced that it will be exhibiting at theWorld ADC Summit, 17-20 February in Frankfurt, in partnership with Aptuit, Glasgow, a pharmaceutical services company, and with support from Scottish Development International (SDI).
More information on the World ADC Summit is available at http://adcsummit-europe.com/.